REQUEST A CONSULTATION

Ready to contact us for a consultation about your condition and our medical services? The staff of our Global Patient Services is ready to help. Please select the appropriate button to get started.
search-icon
News

Non-alcoholic fatty liver disease (NAFLD) could contribute to a higher risk of COVID-19 mortality, new Sheba study indicates

Nonalcoholic Fatty Liver Disease
COVID-19 mortality rates were found to be almost 3 times higher among patients with NAFLD

A new study, headed by Dr. Yana Davidov, senior physician at the Center for Liver Diseases at Sheba Medical Center, found that patients suffering from nonalcoholic fatty liver disease have been observed to be roughly three times as likely to die as a result of a COVID-19 infection compared to patients without NAFLD.

“The virus may attack the liver in a similar manner to the way it attacks the lungs,” said Prof. Ziv Ben-Ari, Head of the Center for Liver Diseases at Sheba Medical Center. According to Ben Ari: “It is also possible that the damage to the liver is caused by the medicine administered to patients as part of their treatment for COVID-19, or as a result of an immunological reaction triggered by the virus, which induces a cytokine storm that can lead to liver inflammation.

382 subjects participated in the study, of which 15.4% had chronic liver disease, with 80% of those suffering from NAFLD. The death rate of patients with nonalcoholic fatty liver disease stood at about 16.7%, as opposed to 6.8% among those without the disease. The data also showed that the more severe the liver condition was, the more likely the patient was to die.

According to Prof. Ben Ari, the results of the study indicate that it may be worth considering adding those suffering from chronic liver diseases, and NAFLD in particular, to the at-risk groups from COVID-19.

Related

Ayelet’s Miracle: The First Woman to Conceive Four Children Following Ovarian Tissue Cryopreservation

At 21, Ayelet Rozenberg was diagnosed with Hodgkin’s lymphoma. Facing aggressive therapies necessary to save her life, Ayelet feared she would never be able to…
Read More
bowel disease
News Sep 07.

Sheba Partners with Biomica to Advance Inflammatory Bowel Disease Care

As part of the new collaboration, Sheba and Biomica will engage in joint microbiome clinical research to develop better treatments for inflammatory bowel disease (IBD)…
Read More
Hemophilia research
News Sep 05.

New Sheba Study Indicates: Novel Treatment Sharply Reduces Bleed Rates Among Hemophilia Patients

Results indicate that a monthly treatment with Fitusiran significantly reduces bleed rates among both hemophilia A and B patients.
Read More